The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Jupiter Endovascular has treated the first two patients in the SPIRARE I study, utilising its Vertex pulmonary embolectomy ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Jupiter Endovascular today announced the first two patients treated in a study of its Vertex pulmonary embolectomy system.

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods.

My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with us. We have Susie Lisa who is Senior Vice President, and Manisha Pai, ...